Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis - PubMed
7 hours ago
- #heart failure
- #HFpEF
- #GLP-1 RA
- Heart failure with preserved ejection fraction (HFpEF) affects 32 million people globally and incurs high healthcare costs.
- GLP-1 receptor agonists (GLP-1 RAs) were studied in six randomized controlled trials involving 5564 HFpEF patients.
- No significant effect was found on cardiovascular mortality or worsening heart failure events, but quality of life improved.
- Safety data favored GLP-1 RAs, though tolerability was similar to placebo.
- Sensitivity analyses excluding older-generation GLP-1 RAs (exenatide) showed a 41% reduction in HF events, suggesting newer agents (semaglutide, tirzepatide) may be more effective.
- GLP-1 RAs appear promising for HFpEF treatment, but further studies are needed.